v3.25.4
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2025
Feb. 13, 2025
USD ($)
security
$ / shares
Award Timing Disclosures [Line Items]    
Award Timing MNPI Disclosure

Policies and Practices Related to the Timing of Grants of Certain Equity Awards

AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year.

These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the high and low trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2025 annual grant was $192.86. The high, low and closing prices of an AbbVie common share on the grant date (February 13, 2025) were $194.28, $191.43, and $193.45 respectively. All LTI awards are subject to a minimum vesting period of 12 months.

​

The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates. The following table presents information regarding option awards granted to our NEOs in the fiscal year ended December 31, 2025, during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such report with the SEC.

  
Award Timing Method

AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year.

These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the high and low trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2025 annual grant was $192.86. The high, low and closing prices of an AbbVie common share on the grant date (February 13, 2025) were $194.28, $191.43, and $193.45 respectively. All LTI awards are subject to a minimum vesting period of 12 months.

  
Award Timing MNPI Considered true  
Award Timing, How MNPI Considered The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates.  
MNPI Disclosure Timed for Compensation Value false  
Awards Close in Time to MNPI Disclosures, Table

​

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Percentage

 

change in the

 

closing market

 

price of the

 

securities

 

underlying the

 

award between

 

the trading day

 

ending

 

immediately

 

prior to the

 

disclosure of

 

material

 

nonpublic

 

information and

 

the trading day

 

beginning

 

immediately

 

following the

 

Number of

Exercise

disclosure of

 

securities

price of the

Grant date fair

material

 

underlying the

award

value of the

nonpublic

 

Name

 

Grant date

 

award

 

($/Share)

 

award

 

Information1

 

Robert A. Michael

 

2/13/2025

 

83,333

 

$

192.86

 

$ 3,199,154

 

1.45

%

Scott T. Reents

 

2/13/2025

 

27,343

 

$

192.86

 

$ 1,049,698

 

1.45

%

Jeffrey R. Stewart

 

2/13/2025

 

33,854

$

192.86

 

$ 1,299,655

 

1.45

%

Azita Saleki-Gerhardt

 

2/13/2025

 

25,000

 

$

192.86

 

$ 959,750

 

1.45

%

Roopal B. Thakkar

 

2/13/2025

 

25,000

$

192.86

 

$ 959,750

 

1.45

%

(1)On February 14, 2025, the company reported its financial results for the fiscal year ended December 31, 2024 on Form 10-K.
  
Michael    
Awards Close in Time to MNPI Disclosures    
Name   Robert A. Michael
Underlying Securities | security   83,333
Exercise Price | $ / shares   $ 192.86
Fair Value as of Grant Date | $   $ 3,199,154
Underlying Security Market Price Change   1.45
Scott T. Reents    
Awards Close in Time to MNPI Disclosures    
Name   Scott T. Reents
Underlying Securities | security   27,343
Exercise Price | $ / shares   $ 192.86
Fair Value as of Grant Date | $   $ 1,049,698
Underlying Security Market Price Change   1.45
Jeffrey R. Stewart    
Awards Close in Time to MNPI Disclosures    
Name   Jeffrey R. Stewart
Underlying Securities | security   33,854
Exercise Price | $ / shares   $ 192.86
Fair Value as of Grant Date | $   $ 1,299,655
Underlying Security Market Price Change   1.45
Azita Saleki-Gerhardt    
Awards Close in Time to MNPI Disclosures    
Name   Azita Saleki-Gerhardt
Underlying Securities | security   25,000
Exercise Price | $ / shares   $ 192.86
Fair Value as of Grant Date | $   $ 959,750
Underlying Security Market Price Change   1.45
Roopal B. Thakkar    
Awards Close in Time to MNPI Disclosures    
Name   Roopal B. Thakkar
Underlying Securities | security   25,000
Exercise Price | $ / shares   $ 192.86
Fair Value as of Grant Date | $   $ 959,750
Underlying Security Market Price Change   1.45